AU2017331260B2 - Anti-cancer agents and preparation thereof - Google Patents

Anti-cancer agents and preparation thereof Download PDF

Info

Publication number
AU2017331260B2
AU2017331260B2 AU2017331260A AU2017331260A AU2017331260B2 AU 2017331260 B2 AU2017331260 B2 AU 2017331260B2 AU 2017331260 A AU2017331260 A AU 2017331260A AU 2017331260 A AU2017331260 A AU 2017331260A AU 2017331260 B2 AU2017331260 B2 AU 2017331260B2
Authority
AU
Australia
Prior art keywords
group
alkyl
compound
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017331260A
Other languages
English (en)
Other versions
AU2017331260A1 (en
Inventor
Arun K. Ghosh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of AU2017331260A1 publication Critical patent/AU2017331260A1/en
Assigned to PURDUE RESEARCH FOUNDATION reassignment PURDUE RESEARCH FOUNDATION Request for Assignment Assignors: Gosh, Arun
Application granted granted Critical
Publication of AU2017331260B2 publication Critical patent/AU2017331260B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2017331260A 2016-09-23 2017-09-22 Anti-cancer agents and preparation thereof Active AU2017331260B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662398783P 2016-09-23 2016-09-23
US62/398,783 2016-09-23
PCT/US2017/052967 WO2018057897A1 (en) 2016-09-23 2017-09-22 Anti-cancer agents and preparation thereof

Publications (2)

Publication Number Publication Date
AU2017331260A1 AU2017331260A1 (en) 2019-05-16
AU2017331260B2 true AU2017331260B2 (en) 2024-11-07

Family

ID=61690726

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017331260A Active AU2017331260B2 (en) 2016-09-23 2017-09-22 Anti-cancer agents and preparation thereof

Country Status (14)

Country Link
US (2) US10858371B2 (https=)
EP (1) EP3515492B1 (https=)
JP (1) JP7111722B2 (https=)
KR (1) KR102646702B1 (https=)
CN (1) CN109862916A (https=)
AU (1) AU2017331260B2 (https=)
BR (1) BR112019005885A2 (https=)
CA (1) CA3037883A1 (https=)
DK (1) DK3515492T3 (https=)
IL (1) IL265521B2 (https=)
MA (1) MA46291A (https=)
MX (1) MX394670B (https=)
RU (1) RU2019111768A (https=)
WO (1) WO2018057897A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7111722B2 (ja) 2016-09-23 2022-08-02 パーデュー・リサーチ・ファウンデーション 抗がん剤およびその調製方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140134193A1 (en) * 2012-11-05 2014-05-15 Pfizer Inc. Spliceostatin analogs and methods for their preparation
US8969405B2 (en) * 2008-06-21 2015-03-03 St. Jude Children's Research Hospital Anticancer compounds and methods of making and using same
WO2015077370A1 (en) * 2013-11-19 2015-05-28 Purdue Research Foundation Anti-cancer agents and preparation thereof
WO2017214423A2 (en) * 2016-06-08 2017-12-14 William Marsh Rice University Derivatives of thailanstatin a, methods of treatment and methods of synthesis thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901464A (fr) 1943-01-23 1945-07-27 Boehringer & Soehne Gmbh Procédé d'obtention de vanilline
US7825267B2 (en) 2006-09-08 2010-11-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Synthesis of FR901464 and analogs with antitumor activity
WO2009031999A1 (en) 2007-09-07 2009-03-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fr901464 and analogs with antitumor activity and method for their preparation
CN101417934B (zh) * 2007-10-24 2012-04-18 国鼎生物科技股份有限公司 分离自牛樟芝萃取物的化合物
NZ602675A (en) 2008-03-18 2014-03-28 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
WO2013130882A1 (en) 2012-02-28 2013-09-06 Fred Hutchinson Cancer Research Center Compositions and methods for treating cancer
WO2014100367A1 (en) 2012-12-21 2014-06-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Synthesis of fr901464 and analogs with antitumor activity
US20140274979A1 (en) 2013-03-13 2014-09-18 Golden Biotechnology Corporation Method for the treatment of fatty liver disease
ES2955206T3 (es) 2013-07-15 2023-11-29 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Derivados de espiroquinoxalina como inhibidores de la muerte celular regulada no apoptótica
KR102092569B1 (ko) * 2013-09-17 2020-03-25 엘지디스플레이 주식회사 터치 스크린 일체형 디스플레이 장치와 이의 구동 방법
JP7111722B2 (ja) 2016-09-23 2022-08-02 パーデュー・リサーチ・ファウンデーション 抗がん剤およびその調製方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969405B2 (en) * 2008-06-21 2015-03-03 St. Jude Children's Research Hospital Anticancer compounds and methods of making and using same
US20140134193A1 (en) * 2012-11-05 2014-05-15 Pfizer Inc. Spliceostatin analogs and methods for their preparation
WO2015077370A1 (en) * 2013-11-19 2015-05-28 Purdue Research Foundation Anti-cancer agents and preparation thereof
WO2017214423A2 (en) * 2016-06-08 2017-12-14 William Marsh Rice University Derivatives of thailanstatin a, methods of treatment and methods of synthesis thereof

Also Published As

Publication number Publication date
IL265521A (en) 2019-05-30
JP2019529563A (ja) 2019-10-17
EP3515492A1 (en) 2019-07-31
DK3515492T3 (da) 2023-08-28
US20210395265A1 (en) 2021-12-23
JP7111722B2 (ja) 2022-08-02
KR20190077340A (ko) 2019-07-03
US10858371B2 (en) 2020-12-08
AU2017331260A1 (en) 2019-05-16
MX2019003368A (es) 2019-09-16
EP3515492A4 (en) 2020-04-08
US20190218228A1 (en) 2019-07-18
MX394670B (es) 2025-03-11
US11851441B2 (en) 2023-12-26
EP3515492B1 (en) 2023-07-26
WO2018057897A1 (en) 2018-03-29
IL265521B2 (en) 2024-09-01
RU2019111768A (ru) 2020-10-23
IL265521B1 (en) 2024-05-01
MA46291A (fr) 2019-07-31
CN109862916A (zh) 2019-06-07
KR102646702B1 (ko) 2024-03-11
BR112019005885A2 (pt) 2020-06-02
CA3037883A1 (en) 2018-03-29
RU2019111768A3 (https=) 2020-11-24

Similar Documents

Publication Publication Date Title
KR20250165440A (ko) 피리도[4,3-d]피리미딘 화합물
PT1813614E (pt) Agentes citotóxicos compreendendo novos derivados de tomaimicina
CN119855820A (zh) 喜树碱类化合物及其制备方法和用途
KR102622152B1 (ko) 신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물
EP4458823A1 (en) Menin inhibitor and use thereof
JP2018123122A (ja) カリケアマイシン誘導体およびその抗体薬物コンジュゲート
JPH08337584A (ja) 縮合六環式アミノ化合物、これを含有する医薬及びその製法
EP4711371A1 (en) Camptothecin derivative, linker, ligand-drug conjugate and medical use thereof
AU2023301282A1 (en) Compound comprising self-immolative group and ligand-drug conjugate comprising same
US9828405B2 (en) Morpholinyl anthracycline derivatives
CN109180681B (zh) 一种dna毒性二聚体化合物
AU2017331260B2 (en) Anti-cancer agents and preparation thereof
TW200404806A (en) Camptothecins with a modified lactone ring
WO2018089621A1 (en) Tricyclic p2-ligand containing potent hiv-protease inhibitors against hiv/aids
KR102481799B1 (ko) 칼리스폰기올리드, 그의 유사체 및 그의 용도
CN117986269A (zh) 喜树碱衍生物及其制备方法和应用
KR102717168B1 (ko) 표적 단백질의 분해를 유도하기 위한 데그라듀서, 이의 제조방법 및 이를 유효성분으로 함유하는 표적 단백질 관련 질환의 예방 또는 치료용 약학적 조성물
HK40006497A (en) Anti-cancer agents and preparation thereof
US12415789B2 (en) Macrocycles comprising a 4-amido-2,4-pentadienoate moiety for the treatment of hypoxic cancers
RU2823231C1 (ru) Соединение-антагонист PD-L1
HK40111293A (en) Menin inhibitor and use thereof
JP2026059772A (ja) ピリド［４，３－ｄ］ピリミジン化合物

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: PURDUE RESEARCH FOUNDATION

Free format text: FORMER APPLICANT(S): GOSH, ARUN

FGA Letters patent sealed or granted (standard patent)